Overview

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
0
Participant gender:
Female
Summary
The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UConn Health
Collaborator:
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel
Criteria
Inclusion Criteria:

- diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian
carcinoma,

- stage III suboptimal surgery or biopsy,

- stage IV disease

- no prior chemotherapy

Exclusion Criteria:

- unstable heart conditions

- high blood pressure

- vascular disorders

- bleeding problems